Background: Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.Methods: Patients considered AS‐eligible (NCCN low‐favorable intermediate risk) but proceeded to RP from February 2012 to September 2024 were identified from our prospective institutional database. Outcomes were classified by presence or absence of APF at RP, which was defined as grade group (GG) ≥ 3, pT3b, or pN1 disease. Previously established genomic signatures of interest were compared between the two groups. Scaled multivariable logistic regression was performed to evaluate associations between multiple genomic classification systems and the outcome of APF.Results: There were 184 AS‐eligible patients, of whom 153 (83.2%) had favorable intermediate risk disease and 31 (16.8%) had low risk disease. There were 41 patients (22.3%) who had APF at RP. The incidence of favorable intermediate risk disease did not differ between those with and without APF (80.5% vs. 83.9%, p = 0.64). Patients with APF had a higher baseline PSA (5.6 ng/mL vs. 4.9 ng/mL, p = 0.01) and Decipher score (0.55 vs. 0.41, p = 0.004) compared to those without APF. On scaled logistic regression with adjustment for log‐transformed PSA, the Decipher score, PTEN loss, activated CD4, and ERG positive rate were significantly associated with APF (OR 1.61, 95% CI 1.11–2.32, p = 0.01). Of ten other previously published genomic classifiers, nine were significantly associated with APF.Conclusion: AS‐eligible patients with APF at RP demonstrate differences in gene expression when compared to those without APF. We established that multiple existing genomic classifiers not previously studied in this context demonstrate the ability to predict APF in this patient population. Inclusion of genomics in the risk stratification of AS‐eligible patients has the potential to better inform clinical decisions.
Due to advancements in medical care and reconstructive surgery, more patients with bladder exstrophy are reaching reproductive age and considering pregnancy. Complications are more common during pregnancy in this patient population, given medical comorbidities and prior surgical intervention. In the case of cesarean delivery, careful planning is necessary to prevent inadvertent injury to the bladder or bowel segments. This report concerns a patient with a history of infant closure of bladder exstrophy, followed by two bladder augmentations and a catheterizable channel who presented for care at 9 weeks of gestation. Magnetic resonance imaging (MRI) at 36 weeks of gestation was used to delineate the anatomy in planning for cesarean delivery. The patient underwent a successful cesarean delivery at 38 weeks 1 day of gestation. Patients with prior urologic reconstruction can undergo safe cesarean delivery if proper surgical planning is performed. Multidisciplinary care and prenatal MRI are valuable tools for avoiding surgical complications.
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.